Who Supplies Pantoprazole to India from NETHERLANDS

To import finished pharmaceutical formulations containing Pantoprazole into India, the foreign manufacturer must obtain a Drug Import License from the Directorate General of Foreign Trade (DGFT). Additionally, the product must be registered with the Central Drugs Standard Control Organization (CDSCO). This involves submitting Form 40 or 41, along with the necessary documentation, to the CDSCO. The registration process typically takes 6 to 12 months, depending on the completeness of the application and compliance with regulatory requirements. Pantoprazole formulations under HS Code 30049039 are classified as "Other" under the category of antiulcer drugs and require adherence to specific quality and safety standards set by the CDSCO.

Imported Pantoprazole formulations must undergo quality testing at CDSCO-approved laboratories to ensure compliance with Indian Pharmacopoeia standards. Each batch requires a Certificate of Analysis (CoA) and stability data demonstrating a shelf life of at least 24 months under ICH Zone IV conditions. Port inspection by customs drug inspectors is mandatory to verify the authenticity and quality of the product. If a batch fails quality testing, it may be rejected, leading to potential delays and financial losses for the importer.

Between 2024 and 2026, the CDSCO has implemented stricter regulations for the import of finished pharmaceutical formulations, including Pantoprazole. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially reducing reliance on imports. Bilateral agreements between India and the Netherlands have facilitated smoother trade processes, but importers must stay updated on policy changes to ensure compliance.

India imports finished Pantoprazole formulations to meet the demand for patented and branded products, as well as specific dosage forms not produced domestically. The market size for Pantoprazole formulations in India is substantial, with a growing need for diverse formulations to cater to various patient requirements. Domestic capacity may not fully meet this demand, leading to continued import dependency.

The Basic Customs Duty (BCD) for Pantoprazole formulations under HS Code 30049039 is 10%. An additional Social Welfare Surcharge (SWS) of 10% is applied. The Integrated Goods and Services Tax (IGST) is applicable at the prevailing rate for pharmaceutical products. There are no exemptions or preferential rates for imports from the Netherlands. The total landed duty percentage is calculated by summing the BCD, SWS, and IGST.

India sources Pantoprazole formulations from the Netherlands due to the country's strong pharmaceutical manufacturing capabilities, adherence to international quality standards, and the availability of specialized dosage forms. While other suppliers like China, Germany, and the US also export Pantoprazole formulations to India, the Netherlands offers a competitive advantage in terms of product quality and regulatory compliance. The Netherlands holds a significant share in the Indian market for imported Pantoprazole formulations.

India imports Pantoprazole formulations from the Netherlands due to the availability of patented formulations, specialized dosage forms, and technology-licensed products that are not manufactured domestically. The Netherlands provides formulations containing Pantoprazole that meet international quality standards and regulatory requirements, fulfilling specific market needs in India.

Compared to other origins like China, the European Union, and the United States, the Netherlands offers advantages in terms of product quality, regulatory compliance, and reliability. While other countries may offer competitive pricing, the Netherlands's adherence to stringent quality standards and consistent supply chain reliability make it a preferred source for Pantoprazole formulations.

Potential risks for Indian importers include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have occurred due to supply chain disruptions; therefore, importers should implement risk mitigation strategies.

1. 1Engage in dual-sourcing strategies to mitigate supply chain risks.
2. 2Maintain optimal inventory levels to buffer against potential disruptions.
3. 3Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Establish clear Minimum Order Quantities (MOQs) with suppliers.
5. 5Conduct thorough supplier qualification processes to ensure compliance with quality and regulatory standards.

1. 1Obtain a valid Importer Exporter Code (IEC) from the DGFT.
2. 2Register the product with the CDSCO by submitting Form 40 or 41.
3. 3Secure a Drug Import License from the CDSCO.
4. 4Obtain a No Objection Certificate (NOC) from the CDSCO, if required.
5. 5Engage a licensed customs broker for import clearance.
6. 6Seek an advance ruling for HS Code 30049039, if necessary.

1. 1Certificate of Analysis (CoA) for each batch.
2. 2Certificate of Pharmaceutical Product (CoPP).
3. 3Good Manufacturing Practice (GMP) certificate.
4. 4Drug Master File (DMF) for the product.
5. 5Stability data demonstrating a shelf life of at least 24 months under ICH Zone IVa/IVb conditions.
6. 6Free Sale Certificate indicating the product is freely sold in the country of origin.
7. 7Manufacturer's authorization letter.

Upon arrival, customs drug inspectors will collect samples of the imported Pantoprazole formulations for quality testing. Mandatory batch testing is conducted to ensure compliance with Indian Pharmacopoeia standards. The testing process may take several weeks, during which the goods are held at the port. If a batch fails quality testing, it may be rejected, leading to potential delays and financial losses for the importer. Common quality issues from Netherlands suppliers include discrepancies in labeling and packaging, which can lead to delays in clearance.

1. 1Renew CDSCO registration annually.
2. 2Undergo periodic audits in the Netherlands to ensure continued compliance with GMP standards.
3. 3Implement change control procedures to manage any modifications in manufacturing processes.
4. 4Establish a